What it sells
AI chronic disease screening.
Business model breakdown
Workflow: what inputs become what output?
Capture fundus image, AI screens glaucoma, diabetic retinopathy, macular degeneration plus cardiovascular/kidney risk, refer to care and continue chronic-disease follow-up.
Distribution: how it reaches customers
Direct inquiries plus distribution agreement with Daewoong Pharmaceutical; overseas approvals in 6 countries.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-03-06 | — | $13.7M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.